teaser
H. Lundbeck A/S announces the initiation of a multi-centre, placebo-controlled, fixed-dose study of Lu AE58054
The study of Lu AE58054 is an add-on to donepezil in patients with moderate Alzheimer’s disease.
“Alzheimer’s disease is one of the most complex and challenging areas of research and development, but also an area with huge unmet medical needs,” says Executive Vice President Anders Gersel Pedersen, Head of Drug Development at Lundbeck.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
“We are very pleased that Lundbeck can continue to deliver projects that potentially can alter the course of this debilitating neurological disease and radically change the lives of patients.”
